Personalized medicine: Predicting responses to therapy in patients with RA

Current Opinion in Pharmacology

Volumn 13, Issue 3, 2013, Pages 463-469

  Van Den Broek, Marianne ^a   Visser, Karen ^a   Allaart, Cornelia F ^a   Huizinga, Tom W J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MONOTHERAPY; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; INDIVIDUALIZED MEDICINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879100481     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.03.006     Document Type: Review

References (35)

1. N. Vastesaeger, S. Xu, D. Aletaha, E.W. St Clair, and J.S. Smolen A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis Rheumatology (Oxford) 48 2009 1114 1121
2. Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, C.F. Allaart, Z.D. van, P.J. Kerstens, and J.M. Hazes Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial Arthritis Rheum 52 2005 3381 3390
3. K. Visser, Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, H.K. Ronday, P.E. Seys, and P.J. Kerstens A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study Ann Rheum Dis 69 2010 1333 1337
4. B. Fautrel, B. Granger, B. Combe, A. Saraux, F. Guillemin, and L.X. Le Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort Arthritis Res Ther 14 2012 R249
5. S. Lillegraven, N. Paynter, F.H. Prince, N.A. Shadick, E.A. Haavardsholm, and M.L. Frits The performance of matrix-based risk models for rapid radiographic progression in BRASS, a cohort of patients with established rheumatoid arthritis Arthritis Care Res (Hoboken) 2012 (epublication ahead of print)
6. B. Fautrel, B. Granger, B. Combe, F. Guillemin, A. Saraux, and X. Le Loët Value of matrices developed to identify early rheumatoid arthritis patients with rapid radiographic progression despite methotrexate therapy: a comparison of their performance in the early rheumatoid arthritis ESPOIR cohort Arthritis Rheum 64 2012 S786 S787
7. M. van den Broek, L. Dirven, J.K. de Vries-Bouwstra, A.J. Dehpoor, Y.P. Goekoop-Ruiterman, and A.H. Gerards Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up Ann Rheum Dis 71 2012 1530 1533
8. D. Plant, J. Bowes, C. Potter, K.L. Hyrich, A.W. Morgan, and A.G. Wilson Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci Arthritis Rheum 63 2011 645 653
9. M.L. Hetland, I.J. Christensen, U. Tarp, L. Dreyer, A. Hansen, and I.T. Hansen Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry Arthritis Rheum 62 2010 22 32
10. K.L. Hyrich, K.D. Watson, A.J. Silman, and D.P. Symmons Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Rheumatology (Oxford) 45 2006 1558 1565
11. L.E. Kristensen, M.C. Kapetanovic, A. Gulfe, M. Soderlin, T. Saxne, and P. Geborek Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register Rheumatology (Oxford) 47 2008 495 499
12. H. Canhao, A.M. Rodrigues, A.F. Mourao, F. Martins, M.J. Santos, and J. Canas-Silva Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis Rheumatology (Oxford) 51 2012 2020 2026
13. R. Klaasen, T. Cantaert, C.A. Wijbrandts, C. Teitsma, D.M. Gerlag, and T.A. Out The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study Rheumatology (Oxford) 50 2011 1487 1493
14. S. Kleinert, H.P. Tony, A. Krause, M. Feuchtenberger, S. Wassenberg, and C. Richter Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study Rheumatol Int 32 2012 2759 2767
15. F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, and V.R. van The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 2006 26 37
16. M. Dougados, K. Kissel, T. Sheeran, P.P. Tak, P.G. Conaghan, and E.M. Mola Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Ann Rheum Dis 72 2013 43 50
17. L.R. Coulthard, J.C. Taylor, S. Eyre, J.I. Robinson, A.G. Wilson, and J.D. Isaacs Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients Ann Rheum Dis 70 2011 98 103
18. D. Plant, R. Prajapati, K.L. Hyrich, A.W. Morgan, A.G. Wilson, and J.D. Isaacs Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort Arthritis Rheum 64 2012 665 670
19. J. Cui, S. Saevarsdottir, B. Thomson, L. Padyukov, A.H. van der Helm-van Mil, and J. Nititham Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy Arthritis Rheum 62 2010 1849 1861
20. E.J. Toonen, C. Gilissen, B. Franke, W. Kievit, A.M. Eijsbouts, and A.A. den Broeder Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis PLoS ONE 7 2012 e33199
21. T. Lequerre, A.C. Gauthier-Jauneau, C. Bansard, C. Derambure, M. Hiron, and O. Vittecoq Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis Arthritis Res Ther 8 2006 R105
22. K. Kayakabe, T. Kuroiwa, N. Sakurai, H. Ikeuchi, A.T. Kadiombo, and T. Sakairi Interleukin-1beta measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis Rheumatology (Oxford) 51 2012 1639 1643
23. I. Ortea, B. Roschitzki, J.G. Ovalles, J.L. Longo, I. de lT, and I. Gonzalez Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis J Proteomics 77 2012 372 382
24. M.L. Hetland, B. Ejbjerg, K. Horslev-Petersen, S. Jacobsen, A. Vestergaard, and A.G. Jurik MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA) Ann Rheum Dis 68 2009 384 390
25. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study J Nucl Med 52 2011 77 80
26. H.P. Brezinschek, F. Rainer, K. Brickmann, and W.B. Graninger B lymphocyte-typing for prediction of clinical response to rituximab Arthritis Res Ther 14 2012 R161
27. M. Couderc, S. Mathieu, B. Pereira, B. Glace, and M. Soubrier Predictive factors of rituximab response in rheumatoid arthritis: results from a french university hospital Arthritis Care Res (Hoboken) 2012 10.1002/acr.21865 [Epub ahead of print]
28. M. Fabris, L. Quartuccio, S. Lombardi, M. Saracco, F. Atzeni, and A. Carletto The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis Autoimmun Rev 11 2012 315 320
29. H.G. Raterman, S. Vosslamber, R.S. de, M.T. Nurmohamed, W.F. Lems, and M. Boers The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients Arthritis Res Ther 14 2012 R95
30. O. Brocq, E. Millasseau, C. Albert, C. Grisot, P. Flory, and C.H. Roux Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis Joint Bone Spine 76 2009 350 355
31. Y. Tanaka, T. Takeuchi, T. Mimori, K. Saito, M. Nawata, and H. Kameda Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study Ann Rheum Dis 69 2010 1286 1291
32. B. Saleem, H. Keen, V. Goeb, R. Parmar, S. Nizam, and E.M. Hensor Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 69 2010 1636 1642
33. M. van den Broek, N.B. Klarenbeek, L. Dirven, S.D. van, H.M. Hulsmans, and P.J. Kerstens Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study Ann Rheum Dis 70 2011 1389 1394
34. A. Kavanaugh, P. Emery, R. Fleischmann, R.F. van Vollenhoven, K. Pavelka, and P. Durez Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial Arthritis Rheum 63 2011 S665 S666
35. Y. Tanaka, S. Hirata, S. Fukuyo, M. Nawata, S. Kubo, and K. Yamaoka Discontinuation of adalimumab without functional and radiographic damage progression after achieving sustained remission in patients with rheumatoid arthritis (the HONOR study): 1-year results Arthritis Rheum 64 2012 s333